Infertility Drugs Market Size - By Drug Class, By Route of Administration, By Gender, By Distribution Channel - Global Forecast, 2025 - 2034

Infertility Drugs Market Size

The global infertility drugs market was valued at USD 4 billion in 2024. The market is anticipated to grow from USD 4.2 billion in 2025 to USD 7.3 billion in 2034, growing at a CAGR of 6.2% from 2025 to 2034.
 

The growth of the infertility drugs industry is largely driven by the increase in the number of people suffering from infertility. High stress due to excessive workload, obesity, shifting age for first-time parenthood, and a sedentary lifestyle are some of the major factors contributing to decreased fertility in both sexes. For example, as per the WHO, around 17.5% of the adult population – roughly 1 in 6 worldwide experience infertility, showing the urgent need to increase access to affordable, high-quality fertility care for those in need. These growing numbers are reinforcing the need for effective medicines, driving innovations in the R&D of infertility drugs, and thus boosting market growth.
 

Governments across the globe are launching several programs to help people with infertility problems by offering insurance coverage for therapy. From April 2022, Japan's public health insurance began reimbursing fertility treatments, aiming to increase accessibility and reduce the financial burden on patients. This policy covers various treatments, including in vitro fertilization (IVF), with an aim to make the treatments more accessible to patients by effectively lowering the cost by 70%.  Such initiatives will accelerate market growth.
 

It is also anticipated that the availability of a wide range of medications for the treatment of infertility issues will benefit the industry. Furthermore, increased accessibility to advanced treatments owing to infrastructure development, especially in the emerging regions, is expanding the market for infertility medication. Countries in the Asia Pacific, Latin America, and Middle East are prioritizing modernization in healthcare and reproductive services. With specialized fertility clinics, trained specialists, and modernized healthcare systems, more people have the accessibility to undergo infertility treatments. In addition, rising disposable income and better insurance coverage in these regions are empowering people to obtain expensive infertility drugs and treatments, thus increasing the adoption of infertility drugs and fostering market growth.
 

Infertility drugs are specifically designed to address and treat infertility-related issues in individuals or couples. These drugs are formulated to regulate hormone levels, stimulate ovulation, improve sperm production or quality, enhance the chances of successful fertilization, or address underlying medical conditions that contribute to infertility.
 

Infertility Drugs Market Trends

• The most significant trend influencing the market for infertility medications is the global shift toward a delayed age for parenthood, particularly in urban populations. Greater female workforce participation, pursuit of advanced education, and evolving social attitudes have raised the average age of prospective parents.
   
• For example, studies suggest that the mean age of having the first child has increased by 1 year per decade since the 1970s. According to a report from the Centers for Disease Control and Prevention, the average (or mean) age of mothers for all births rose from 24.6 years to 27.2 over the past three decades.
   
• Since fertility naturally declines with advancing age, especially among women over 35, this postponement often requires some form of intervention, including the use of fertility drugs. This has stimulated the demand for infertility drugs used for ovulation induction, and sophisticated combination medications that aid reproduction in older women. As a result, the pharmaceutical industry is focusing its primary efforts on the development of more sophisticated age-related infertility therapies.
   
• The market is also propelled by increased use of combination therapies, complex treatment plans, and personalized approach to therapy. Instead of single-drug therapy, practitioners are using more sophisticated multi-drug regimens that more efficiently correct hormonal disorders, PCOS, endometriosis, or sometimes even infertility of unknown origin.
   
• Advances in genomic and hormonal analyses are enabling a more tailored approach to fertility medications based on a woman's hormonal profile, age, and past pregnancies. This increases the use of selective estrogen receptor modulators (SERMs) such as clomiphene combined with gonadotropins or metformin for the treatment of PCOS, which opens new opportunities for innovation and product differentiation.
   
• Moreover, with growing awareness and diagnostics for male factors like a low sperm count, poor sperm motility, and hormonal imbalances, there has been an increase in the uptake of male infertility drugs. These include hormonal therapies such as gonadotropins (hCG, hMG) and dopamine agonists used for hyperprolactinemia.
   
• The removal of stigma surrounding male infertility combined with better diagnostic tools like semen analysis and DNA fragmentation tests, is helping men to opt for pharmacological treatment. This is likely to expand the male as well as female infertility drugs market substantially in the foreseeable future.
   
• Further, the growth of assisted reproductive technology (ART) centers and fertility clinics, particularly in developing nations, is being accompanied by an increasing parallel demand for infertility drugs. Countries such as India, China, Brazil, and certain areas in the Middle East are making significant investments in reproductive medicine healthcare infrastructure. All these factors combined are driving growth and innovation in the market.
   

Infertility Drugs Market Analysis

Based on the drug class, the infertility drugs industry is classified into gonadotropins, aromatase inhibitors, selective estrogenic receptor modulators (SERMs), dopamine agonists, and other drug classes. The gonadotropins segment was valued at USD 1.7 billion in 2024 and is projected to witness robust growth over the analysis timeframe.
 

• Due to its role in promoting ovulation and enhancing fertility results, the gonadotropin segment dominates with a high market share in the market.
   
• Human menopausal gonadotropin (hMG), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) gonadotropins are commonly administered to women and men undergoing fertility treatments. Their action on the ovaries to trigger follicular maturation, and in men to stimulate spermatogenesis, makes them a cornerstone in assisted reproductive techniques (ART) like in vitro fertilization (IVF) and intrauterine insemination (IUI).
   
• Also, the growing adoption of assisted reproductive technologies (ART), where gonadotropins play a crucial role, increases the demand for these drugs, thereby driving segmental growth. For instance, in 2022, there were 435,426 ART cycles performed in the U.S.
   
• Further, innovations in drug discovery and research are leading to the development of more refined and targeted gonadotropin formulations. These modern gonadotropins exhibit improved efficacy and safety profiles, minimizing the risk of side effects and complications, thereby fostering market growth.
   

Based on the route of administration, the global infertility drugs market is categorized into parenteral, oral, and topical. The oral segment dominated the market with 58.1% market share in 2024.
 

• High market share of the oral segment can be attributed to its ease of use, patient adherence, low cost, and convenience. Few of the commonly used first-line drugs for ovulation induction include clomiphene citrate (a selective estrogen receptor modulator), letrozole (an aromatase inhibitor), and metformin.
• The ease of administration significantly helps encourage long-term adherence, which is critical in achieving desirable fertility results.
   
• Cost-effectiveness also plays a critical role in the increasing market share of oral drugs for infertility. Compared to injectable gonadotropins or advanced assisted reproductive technologies (ART), oral medications are significantly less expensive, which further drives the adoption of these drugs.
   

Based on the gender, the global infertility drugs market is divided into female and male. The female segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 6.5%.
 

• One of the key drivers for the market is the rise in female infertility occurrences. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., among married women aged 15 to 49 years with no prior births, about 1 in 5 (19%) are unable to get pregnant after one year of infertility.
   
• Similarly, about 1 in 4 (26%) women in this group have difficulty getting pregnant or carrying a pregnancy to term (impaired fecundity). Thus, increasing female infertility will accelerate the segmental growth.
   
• The increasing prevalence of Polycystic Ovary Syndrome (PCOS) among women is also anticipated to boost the segment growth.
   

Based on the distribution channel, the global infertility drugs market is classified into hospital pharmacies, specialty and retail pharmacies, and online pharmacies. In 2024, the hospital pharmacies segment held the highest market share and is expected to showcase significant growth over the analysis period to reach USD 4.2 billion by 2034.
 

• Increasing prevalence of infertility coupled with rising healthcare awareness will fuel the demand for specialized medications. Hospital pharmacies, with their comprehensive range of infertility drugs, are well-positioned to meet this demand and ensure their availability within the hospital setting, thereby boosting the segmental growth.
   
• The advanced pharmaceutical infrastructure and expertise of hospital pharmacies allow for personalized and tailored treatments, further contributing to their growth in this segment.
   
• Moreover, hospitals, especially those with in-house fertility centers, tend to stock a comprehensive range of infertility drugs, ensuring that patients receive timely and accurate treatments. This integration reduces delays in medication initiation and improves patient compliance, making hospital pharmacies a critical distribution channel for infertility drugs.
   

North America infertility drugs market accounted for 42.6% market share in the global market in 2024 and is anticipated to witness high growth during the forecast timeframe.
 

The U.S. market was valued at USD 1.34 billion and USD 1.4 billion in 2021 and 2022, respectively. The market size reached USD 1.54 billion in 2024, growing from USD 1.46 billion in 2023.
 

• The U.S. holds a dominant position in the global market owing to its sophisticated healthcare system and a well-informed population, along with a significantly high number of patients needing treatment.
   
• Fertility clinics are equipped with the latest technologies, which enable the provision of accurate diagnoses as well as the formulation of customized treatment plans that encompass the prescription of ovulation-inducing medications and hormone therapies.
   
• In addition, the availability of numerous FDA-approved infertility drugs, including but not limited to gonadotropins, aromatase inhibitors, and selective estrogen receptor modulators (SERMs), ensures patients receive safe and effective treatment.
   
• The rapid innovation, effective distribution, and streamlined phases of clinical trials by the well-known pharmaceutical companies based in the U.S. also strengthen the country’s position in the market.
   

Europe infertility drugs market accounted for more than USD 1 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe’s extensive healthcare system, high public awareness, and favorable reimbursement policies support market growth.
   
• Most European nations, especially in Western Europe like Germany, France, UK, and Italy, have incorporated infertility treatment into public healthcare systems, which alleviates some financial burdens, thus promoting the adoption of infertility drugs.
   
• These factors, coupled with the region’s ageing population, delayed family planning, and increased career focus, have led to a surge in infertility, which drives the demand for pharmacological treatments.
   
• Further, Europe’s well-established regulatory frameworks that govern the safety, efficacy, and quality of the pharmaceutical sector strengthen its position in the market.
   

Germany infertility drugs market is anticipated to witness considerable growth over the analysis period.
 

• Germany holds a notable share in the Europe market due to the country's advanced healthcare system and significant focus on reproductive health. Fertility drug use in the country is enhanced by government support policies through public and private insurance.
   
• Germany’s demographic shifts have also played a role in contributing to the market share. With the average age of first-time parents steadily increasing, along with a growing prevalence of infertility due to lifestyle choices, there is enhanced demand for effective fertility therapies across the country.
   
• For example, in Germany, the average age for both first-time mothers and fathers is increasing. First-time mothers in Germany are now, on average, over 30 years old, with the average age at first birth being around 30.3 years. Fathers are also getting older, with the average age at the birth of their first child being 33.2 years.
   
• In addition, Germany serves as the central center for pharmaceutical research and production in Europe. Several of the leading infertility drug developers, both foreign and local biopharma companies, have a significant presence in the country, which further enhances the country's position in the global market.
   

The Asia Pacific infertility drugs market is anticipated to witness significant growth over the analysis timeframe.
 

• The Asia Pacific region has been experiencing rapid growth in the infertility drugs industry due to a mix of socioeconomic and demographic trends alongside the region's advancing healthcare system.
   
• One of the noteworthy factors is the growing uptake of infertility treatment services, now recognized as a public health issue in countries like China, India, Japan, and South Korea.
   
• For example, China’s 2022 total fertility rate is estimated to be 1.18 children per woman, down substantially from earlier decades and significantly below the replacement rate of 2.1 children per woman.
   
• Falling fertility rates have been attributed to rising urbanization, changing lifestyles, the postponement of childbearing, poor nutrition, and heightened stress levels.
   
• Increased awareness of fertility diagnostic services tends to push couples to seek treatment. This, coupled with the region’s improved access to health care, fuels the demand for infertility drugs.
   

India infertility drugs market is predicted to grow significantly over the forecast period.
 

• The increasing infertility rate in India, coupled with a rise in awareness regarding reproductive health, is helping the country to emerge as a major contributor to the growth of the Asia Pacific market.
   
• Factors such as inactive lifestyle, stress, improper eating habits, and a growing prevalence of PCOS and endometriosis are fueling infertility in women and men alike. For instance, studies suggest that out of 60–80 million couples suffering from infertility globally, 15–20 million (25%) are in India. This, in turn, has stimulated the need for treatments including drugs to relieve infertility.
   
• In addition, growing awareness of the availability of infertility drugs in India's emerging urban population is influencing the growth of the market.
   

Brazil is experiencing significant growth in the Latin America infertility drugs market.
 

• The increased acceptance and awareness of infertility treatments is supporting the growth of Brazil in the Latin America market.
   
• Infertility issues have seen a rise in the country due to societal changes like marriages and childbirths being postponed because of career paths and financial planning.
   
• For instance, in 2023, Brazil's total fertility rate was 1.62 children per woman, which is the lowest it has been, according to Statista.
   
• Furthermore, the rapid growth of specialized fertility clinics in the country, which offer sophisticated reproductive technologies and drug therapies, has contributed to the market growth.
   

Saudi Arabia infertility drugs industry is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• Saudi Arabia's market is rapidly expanding, largely due to increased acceptance and understanding of infertility treatment options.
   
• Coupled with this, the rise in obesity, smoking, and the trend of getting married later in life are also fueling the problem of infertility and widening the population of patients who need drug treatment.
   

Infertility Drugs Market Share

Competition in the infertility drugs industry is marked by well-established companies, emerging firms, and local players fighting to capture a larger share of the market. The top 4 players such as Merck KGaA, Ferring Pharmaceuticals, Bayer, and Pfizer account for approximately 60% - 65% of the global market. These key players focus on various strategies such as acquisitions, business expansion and novel product launches to consolidate their market presence.
 

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.
 

Bayer AG is a notable player in the infertility drugs market, primarily offering Clomid (clomiphene citrate) and supporting treatments. The company leverages its broad expertise in women’s health and hormone therapies to strengthen its fertility drug offerings globally. Bayer actively invests in clinical research and collaborates with fertility clinics to optimize treatment protocols. Furthermore, Bayer is exploring digital health initiatives and patient support programs to improve accessibility and adherence, aiming to enhance overall treatment success rates in infertility care.
 

Ferring Pharmaceuticals is a leading player in the market, specializing in reproductive health and fertility treatments. The company offers a robust portfolio of infertility medications, including gonadotropins and hormone therapies, aimed at improving conception rates. Ferring’s strong focus on research and innovation has helped it maintain a competitive edge globally, especially in assisted reproductive technologies (ART). Their commitment to personalized patient care supports their growing presence in both developed and emerging markets.
 

Infertility Drugs Market Companies

Few of the prominent players operating in the infertility drugs industry include:

• Abbott Laboratories
• Bayer
• Besins Healthcare
• EMD Serono (Merck KGaA)
• Ferring Pharmaceuticals
• Intas Pharmaceuticals
• Livzon
• Mankind Pharma
• Merck & Co.
• Novartis
• Organon & Co.
• Pfizer
• Sanofi
• Sun Pharmaceutical
• Teva Pharmaceutical
   

Infertility Drugs Industry News

• In June 2022, Mankind Pharma developed and launched a generic version of Dydrogestrone tablets for the treatment of patients’ pregnancy-related complications in India. This drug was an equivalent version of Abbott Duphaston tablets. This launch helped the company expand its business in the infertility treatment market.
   
• In August 2021, Merck Specialties Pvt ltd, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. The Pergoveris Pen provide combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. This strategy helped the company to enhance its product offering in infertility drugs industry and assist in strengthening the market position.
   
• In December 2019, Mankind Pharma launched its generic Dydrogesterone tablets for treatment of infertility and pregnancy related complications in the Indian market. The company’s product is generic version of Abbott’s Duphaston tablets. This strategy helped the company to expand and grow.
   

The infertility drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Gonadotropins
• Aromatase inhibitors
• Selective estrogen receptor modulators (SERMs)
• Dopamine agonists
• Other drug classes

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Gender

• Female
• Male

Market, By Distribution Channel

• Hospital pharmacies
• Specialty and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE